Nuclear initiated NF-κB signaling: NEMO and ATM take center stage

Cell Research

Volumn 21, Issue 1, 2011, Pages 116-130

  Miyamoto, Shigeki ^a  

^a University of Wisconsin Health   (United States)

Author keywords

ATM; DNA damage; DNA damage response; IKK; NEMO; NF B; SUMO

Indexed keywords

ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; I KAPPA B KINASE; IKBKG PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

DNA DAMAGE; DNA REPAIR; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; I-KAPPA B KINASE; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 78650873024     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.179     Document Type: Review

References (120)

1. Perkins ND. Integrating cell-signalling pathways with NF-κ and IKK function. Nat Rev Mol Cell Biol 2007; 8:49-62.
2. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
3. Ghosh S, Hayden MS. New regulators of NF-κ in inflammation. Nat Rev Immunol 2008; 8:837-848.
4. Hayden MS, Ghosh S. Shared principles in NF-κ signaling. Cell 2008; 132:344-362.
5. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-κ regulatory pathways. Annu Rev Biochem 2009; 78:769-796.
6. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986. 46: 705- 716.
7. J Immunol 2006; 177:7485-7496.
8. Sen R, Baltimore D. Inducibility of κ immunoglobulin enhancer- binding protein NF-κ by a posttranslational mechanism. Cell 1986; 47:921-928.
9. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988; 242:540-546.
10. Wu ZH, Miyamoto S. Many faces of NF-κ signaling induced by genotoxic stress. J Mol Med 2007; 85:1187-1202.
11. Janssens S, Tschopp J. Signals from within: the DNAdamage- induced NF-κ response. Cell Death Differ 2006; 13:773-784.
12. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003; 22:5813-5827.
13. Salminen A, Suuronen T, Huuskonen J, Kaarniranta K. NEMO shuttle: a link between DNA damage and NF-κ activation in progeroid syndromes? Biochem Biophys Res Commun 2008; 367:715-718.
14. Ahmed KM, Li JJ. ATM-NF-κ connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007; 7:335-342.
15. Habraken Y, Piette J. NF-κ activation by double-strand breaks. Biochem Pharmacol 2006; 72:1132-1141.
16. Wu ZH, Wong ET, Shi Y, et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell 2010; 40:75-86.
17. Wu ZH, Miyamoto S. Induction of a pro-apoptotic ATM-NF-κB pathway and its repression by ATR in response to replication stress. EMBO J 2008; 27:1963-1973.
18. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179-204.
19. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21:245-255.
20. Derheimer FA, Kastan MB. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 2010; 584:3675-3681.
21. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004; 118:9-17.
22. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-1078.
23. Lin L, DeMartino GN, Greene WC. Cotranslational biogenesis of NF-κ p50 by the 26S proteasome. Cell 1998; 92:819-828.
24. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κ signaling pathway. Science 2001; 293:1495-1499.
25. Xiao G, Harhaj EW, Sun SC. NF-κ-inducing kinase regulates the processing of NF-κ2 p100. Mol Cell 2001; 7:401-409.
26. Basak S, Hoffmann A. Crosstalk via the NF-κ signaling system. Cytokine Growth Factor Rev 2008; 19:187-197.
27. Huxford T, Huang DB, Malek S, Ghosh G. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-κ inactivation. Cell 1998; 95:759-770.
28. Jacobs MD, Harrison SC. Structure of an IκBα/NF-κ complex. Cell 1998; 95:749-758.
29. Rice NR, MacKichan ML, Israel A. The precursor of NF-κ p50 has IκB-like functions. Cell 1992; 71:243-253.
30. Mercurio F, DiDonato JA, Rosette C, Karin M. p105 and p98 precursor proteins play an active role in NF-κ-mediated signal transduction. Genes Dev 1993; 7:705-718.
31. Beg AA, Baltimore D. An essential role for NF-κ in preventing TNF-a-induced cell death. Science 1996; 274:782-784.
32. Tanaka M, Fuentes ME, Yamaguchi K, et al. Embryonic lethality, liver degeneration, and impaired NF-κ activation in IKK-b-deficient mice. Immunity 1999; 10:421-429.
33. Li ZW, Chu W, Hu Y, et al. The IKKb subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999; 189:1839-1845.
34. Li Q, Estepa G, Memet S, Israel A, Verma IM. Complete lack of NF-κ activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev 2000; 14:1729-1733.
35. Makris C, Godfrey VL, Krahn-Senftleben G, et al. Female mice heterozygous for IKKg/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000; 5:969-979.
36. Schmidt-Supprian M, Bloch W, Courtois G, et al. NEMO/ IKKg-deficient mice model incontinentia pigmenti. Mol Cell 2000; 5:981-992.
37. Rudolph D, Yeh WC, Wakeham A, et al. Severe liver degeneration and lack of NF-κ activation in NEMO/IKKgdeficient mice. Genes Dev 2000; 14:854-862.
38. Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev 2006; 210:171-186.
39. Weih F, Caamano J. Regulation of secondary lymphoid organ development by the nuclear factor-κB signal transduction pathway. Immunol Rev 2003; 195:91-105.
40. Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UVinduced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol 1989; 9:5169-5181.
41. Knebel A, Rahmsdorf HJ, Ullrich A, Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J 1996; 15:5314-5325.
42. Kokura S, Yoshida N, Sakamoto N, et al. The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-κ. Cancer Lett 2005; 229:223-233.
43. van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80:1526-1533.
44. van Maanen JM, Verkerk UH, Broersen J, et al. Semi-quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Radic Res Commun 1988; 4:371-384.
45. Mikkelsen RB, Wardman P. Biological chemistry of reactive transduction mechanisms. Oncogene 2003; 22:5734-5754.
46. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007; 6:789-801.
47. Tsuchiya Y, Asano T, Nakayama K, et al. Nuclear IKKb is an adaptor protein for IκBa ubiquitination and degradation in UV-induced NF-κ activation. Mol Cell 2010; 39:570-582.
48. Devary Y, Rosette C, DiDonato JA, Karin M. NF-κ activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261:1442-1445.
49. Bender K, Gottlicher M, Whiteside S, Rahmsdorf HJ, Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-κ by UV. EMBO J 1998; 17:5170-5181.
50. Li N, Banin S, Ouyang H, et al. ATM is required for IκB kinase (IKKk) activation in response to DNA double strand breaks. J Biol Chem 2001; 276:8898-8903.
51. Lee SJ, Dimtchev A, Lavin MF, Dritschilo A, Jung M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κ. Oncogene 1998; 17:1821-1826.
52. Piret B, Schoonbroodt S, Piette J. The ATM protein is required for sustained activation of NF-κ following DNA damage. Oncogene 1999; 18:2261-2271.
53. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKg by SUMO-1 and ubiquitin mediates NF-κ activation by genotoxic stress. Cell 2003; 115:565-576.
54. Panta GR, Kaur S, Cavin LG, et al. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-κ through a common MEK/extracellular signal-regulated kinase/ p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004; 24:1823-1835.
55. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-κ signaling in response to genotoxic stimuli. Science 2006; 311:1141-1146.
56. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-κ activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000; 275:9501-9509.
57. Zhang H, Barcelo JM, Lee B, et al. Human mitochondrial topoisomerase I. Proc Natl Acad Sci USA 2001; 98:10608-10613.
58. Wuerzberger-Davis SM, Nakamura Y, Seufzer BJ, Miyamoto S. NF-κ activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene 2007; 26:641-651.
59. Rashi-Elkeles S, Elkon R, Weizman N, et al. Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. Oncogene 2006; 25:1584-1592.
60. Ashburner BP, Shackelford RE, Baldwin AS Jr, Paules RS. Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-κB (NF-κ) in human diploid fibroblasts. Cancer Res 1999; 59:5456-5460.
61. Mabb AM, Wuerzberger-Davis SM, Miyamoto S. PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nat Cell Biol 2006; 8:986-993.
62. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-κ activation in response to DNA damage. Cell 2005; 123:1079-1092.
63. Hur GM, Lewis J, Yang Q, et al. The death domain kinase RIP has an essential role in DNA damage-induced NF-κ activation. Genes Dev 2003; 17:873-882.
64. Manzl C, Krumschnabel G, Bock F, et al. Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol 2009; 185:291-303.
65. Stilmann M, Hinz M, Arslan SC, et al. A nuclear poly(ADPribose)- dependent signalosome confers DNA damage-induced IκB kinase activation. Mol Cell 2009; 36:365-378.
66. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39:8-24.
67. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-κ in ACH-2 and CEM cells. Nucleic Acids Res 1996; 24:4242-4248.
68. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiationinduced NF-κ activation requires PARP-1 function to confer radioresistance. Oncogene 2009; 28:832-842.
69. Jin HS, Lee DH, Kim DH, et al. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-κB activation. Cancer Res 2009; 69:1782-1791.
70. Ducut Sigala JL, Bottero V, Young DB, et al. Activation of transcription factor NF-κ requires ELKS, an IκB kinase regulatory subunit. Science 2004; 304:1963-1967.
71. Hinz M, Stilmann M, Arslan SC, et al. A cytoplasmic ATMTRAF6- cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κ activation. Mol Cell 2010; 40:63-74.
72. Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96:9112-9117.
73. Berchtold CM, Wu ZH, Huang TT, Miyamoto S. Calciumdependent regulation of NEMO nuclear export in response to genotoxic stimuli. Mol Cell Biol 2007; 27:497-509.
74. Bredemeyer AL, Helmink BA, Innes CL, et al. DNA doublestrand breaks activate a multi-functional genetic program in developing lymphocytes. Nature 2008; 456:819-823.
75. Sherman MH, Kuraishy AI, Deshpande C, et al. AID-induced genotoxic stress promotes B cell differentiation in the germinal center via ATM and LKB1 signaling. Mol Cell 2010; 39:873-885.
76. Grosjean-Raillard J, Tailler M, Ades L, et al. ATM mediates constitutive NF-κ activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2009; 28:1099-1109.
77. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131-144.
78. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κ pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-130.
79. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-112.
80. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-κ signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462:104-107.
81. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129:1065-1079.
82. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-870.
83. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-637.
84. Rosato RR, Kolla SS, Hock SK, et al. Histone deacetylase inhibitors activate NF-κ in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010; 285:10064-10077.
85. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 2010; 330:517-521.
86. Lo YC, Lin SC, Rospigliosi CC, et al. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009; 33:602-615.
87. Rahighi S, Ikeda F, Kawasaki M, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κ activation. Cell 2009; 136:1098-1109.
88. Bagneris C, Ageichik AV, Cronin N, et al. Crystal structure of a vFlip-IKKg complex: insights into viral activation of the IKK signalosome. Mol Cell 2008; 30:620-631.
89. Rushe M, Silvian L, Bixler S, et al. Structure of a NEMO/ IKK-associating domain reveals architecture of the interaction site. Structure 2008; 16:798-808.
90. Yoshikawa A, Sato Y, Yamashita M, et al. Crystal structure of the NEMO ubiquitin-binding domain in complex with Lys 63-linked di-ubiquitin. FEBS Lett 2009; 583:3317-3322.
91. Grubisha O, Kaminska M, Duquerroy S, et al. DARPinassisted crystallography of the CC2-LZ domain of NEMO reveals a coupling between dimerization and ubiquitin binding. J Mol Biol 2010; 395:89-104.
92. Agou F, Ye F, Goffinont S, et al. NEMO trimerizes through its coiled-coil C-terminal domain. J Biol Chem 2002; 277:17464-17475.
93. Fontan E, Traincard F, Levy SG, et al. NEMO oligomerization in the dynamic assembly of the IkappaB kinase core complex. FEBS J 2007; 274:2540-2551.
94. Ivins FJ, Montgomery MG, Smith SJ, et al. NEMO oligomerization and its ubiquitin-binding properties. Biochem J 2009; 421:243-251.
95. O'Neill T, Dwyer AJ, Ziv Y, et al. Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem 2000; 275:22719-22727.
96. Palkowitsch L, Leidner J, Ghosh S, Marienfeld RB. Phosphorylation of serine 68 in the IκB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-a-induced NF-κ activity. J Biol Chem 2008; 283:76-86.
97. Cordier F, Grubisha O, Traincard F, et al. The zinc finger of NEMO is a functional ubiquitin-binding domain. J Biol Chem 2009; 284:2902-2907.
98. Laplantine E, Fontan E, Chiaravalli J, et al. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J 2009; 28:2885-2895.
99. Galanty Y, Belotserkovskaya R, Coates J, et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009; 462:935-939.
100. Morris JR, Boutell C, Keppler M, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462:886-890.
101. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-κB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005; 93:1019-1023.
102. Xu Y, Fang F, St Clair DK, et al. SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008; 7:2367-2376.
103. Xu Y, Fang F, Sun Y, St Clair DK, St Clair WH. RelBdependent differential radiosensitization effect of STI571 on prostate cancer cells. Mol Cancer Ther 2010; 9:803-812.
104. Barre B, Perkins ND. The Skp2 promoter integrates signaling through the NF-κ, p53, and Akt/GSK3b pathways to regulate autophagy and apoptosis. Mol Cell 2010; 38:524-538.
105. Anest V, Hanson JL, Cogswell PC, et al. A nucleosomal function for IκB kinase-alpha in NF-κ-dependent gene expression. Nature 2003; 423:659-663.
106. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-a is critical for cytokineinduced gene expression. Nature 2003; 423:655-659.
107. Liao G, Sun SC. Regulation of NF-κ2/p100 processing by its nuclear shuttling. Oncogene 2003; 22:4868-4874.
108. Vatsyayan J, Qing G, Xiao G, Hu J. SUMO1 modification of NF-κ2/p100 is essential for stimuli-induced p100 phosphorylation and processing. EMBO Rep 2008; 9:885-890.
109. Renner F, Moreno R, Schmitz ML. SUMOylation-dependent localization of IKKe in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell 2010; 37:503-515.
110. Zhou D, Brown SA, Yu T, et al. A high dose of ionizing radiation induces tissue-specific activation of nuclear factor-κB in vivo. Radiat Res 1999; 151:703-709.
111. Wang Y, Meng A, Lang H, et al. Activation of nuclear factor κB in vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 2004; 64:6240-6246.
112. Ferrell JE Jr. How regulated protein translocation can produce switch-like responses. Trends Biochem Sci 1998; 23:461-465.
113. Sorensen FB, Jacobsen F. Stereological estimates of nuclear volume in the prognostic evaluation of primary flat carcinoma in situ of the urinary bladder. Histopathology 1991; 18:531-539.
114. Mogensen O, Sorensen FB, Bichel P, Jakobsen A. Nuclear volume and prognosis in ovarian cancer. Int J Gynecol Cancer 1992; 2:141-146.
115. Mogensen O, Sorensen FB, Bichel P, Jakobsen A. Mean nuclear volume: a supplementary prognostic factor in endometrial cancer. Int J Gynecol Cancer 1999; 9:72-79.
116. Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K. Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 1999; 83:222-226. (Pubitemid 29151517)
117. Arai Y, Okubo K, Terada N, et al. Volume-weighted mean nuclear volume predicts tumor biology of clinically organconfined prostate cancer. Prostate 2001; 46:134-141.
118. Dey P, Powari M. Mean nuclear volume in cervical intraepithelial neoplasia and carcinoma. Anal Quant Cytol Histol 2002; 24:70-72.
119. Bonnelykke-Behrndtz ML, Sorensen FB, Damsgaard TE. Stereological quantification of tumor volume, mean nuclear volume and total number of melanoma cells correlated with morbidity and mortality. APMIS 2008; 116:903-911.
120. Ozer E, Canda T, Kuyucuodlu F. p53 mutations in bilateral breast carcinoma. Corrleation with Ki-67 expression and the mean nuclear volume. Cancer Lett 1998; 122:101-106.